文献速递心力衰竭与心肌病

阿片类药物治疗心力衰竭呼吸困难:系统评价与荟萃分析

Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis.
PubMed 文献 · Heart · 2023-06-26

该系统评价纳入8项随机对照试验共271例心衰患者,评估阿片类药物对呼吸困难的影响。荟萃分析显示阿片类药物与安慰剂在呼吸困难上无显著差异(SMD 0.03,95%CI -0.21至0.28),且恶心、呕吐、便秘等不良反应 favoring 安慰剂。结论认为阿片类药物治疗心衰呼吸困难存疑,仅应作为其他措施失败后的最后选择或紧急情况使用。

要点

  • 阿片类药物对心衰患者呼吸困难无显著改善(SMD 0.03,95%CI -0.21至0.28)。
  • 阿片类药物增加呕吐(RR 4.29,95%CI 1.15至16.01)和便秘(RR 4.77,95%CI 1.98至11.53)风险。
  • 仅在其他措施失败或紧急情况下考虑使用阿片类药物。

核心结论

  • 阿片类药物治疗心衰呼吸困难效果不明确,可能仅作为其他措施失败后的最后选择或紧急情况使用。

研究设计与样本

  • 系统评价与荟萃分析,检索Cochrane CENTRAL、MEDLINE和Embase(2021年7月),纳入8项随机对照试验共271例心衰患者。
  • 使用Cochrane RoB 2工具评估偏倚风险,GRADE评估证据确定性,采用随机效应模型进行荟萃分析。

主要发现

  • 7项RCT纳入呼吸困难主要终点荟萃分析,标准化均数差为0.03(95%CI -0.21至0.28),无研究显示干预与安慰剂间有统计学显著差异。
  • 恶心风险比3.13(95%CI 0.70至14.07),呕吐风险比4.29(95%CI 1.15至16.01),便秘风险比4.77(95%CI 1.98至11.53),研究退出风险比4.42(95%CI 0.79至24.87),均 favoring 安慰剂。
  • 所有荟萃分析异质性低(I2均<8%)。

临床怎么用

  • 心衰患者呼吸困难不应常规使用阿片类药物,仅在其他措施失败或紧急情况下作为最后选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For the treatment of breathlessness in heart failure (HF), most textbooks advocate the use of opioids. Yet, meta-analyses are lacking. METHODS: A systematic review was performed for randomised controlled trials (RCTs) assessing effects of opioids on breathlessness (primary outcome) in patients with HF. Key secondary outcomes were quality of life (QoL), mortality and adverse effects. Cochrane Central Register of Controlled Trials, MEDLINE and Embase were searched in July 2021. Risk of bias (RoB) and certainty of evidence were assessed by the Cochrane RoB 2 Tool and Grading of Recommendations Assessment, Development and Evaluation criteria, respectively. The random-effects model was used as primary analysis in all meta-analyses. RESULTS: After removal of duplicates, 1180 records were screened. We identified eight RCTs with 271 randomised patients. Seven RCTs could be included in the meta-analysis for the primary endpoint breathlessness with a standardised mean difference of 0.03 (95% CI -0.21 to 0.28). No study found statistically significant differences between the intervention and placebo. Several key secondary outcomes favoured placebo: risk ratio of 3.13 (95% CI 0.70 to 14.07) for nausea, 4.29 (95% CI 1.15 to 16.01) for vomiting, 4.77 (95% CI 1.98 to 11.53) for constipation and 4.42 (95% CI 0.79 to 24.87) for study withdrawal. All meta-analyses revealed low heterogeneity (I2 in all these meta-analyses was <8%). CONCLUSION: Opioids for treating breathlessness in HF are questionable and may only be the very last option if other options have failed or in case of an emergency. PROSPERO REGISTRATION NUMBER: CRD42021252201.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Gaertner, Fusi-Schmidhauser, Stock, et al. Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis. Heart. 2023. PMID: 36878671. doi:10.1136/heartjnl-2022-322074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。